Conference Forum Director Valerie Bowling and CRAACO Producer Danny McCarthy break down what to expect at the 2025 CRAACO program. This podcast covers the keynotes, panels and key themes for this year's event, including: 

• How to develop a clinical research program within a community cancer center, with Dr Brian Slomovitz, Mount Sinai Medical Center Miami Beach
• Turning clinical environments into learning health systems, with Dr Laura Esserman, UCSF Carol Franc Buck Breast Cancer Center
• How to better partner with multiple location health system structures for clinical trials 
• Addressing medical staff shortages and challenges to support clinical research
• The impact of clinical trial participation on cost and performance in cancer centers
• EHR and AI advancements for clinical research 
• And more 

Want to know more about CRAACO? Visit CRAACOevent.com.

PODD: Partnership Opportunities in Drug Delivery Directors Valerie Bowling and Andrew Goldstein break down what to expect at PODD 2025. This podcast covers keynotes and key themes for this year's event, including:

• Regeneron Co-Founder and CSO, Dr George Yancopoulos
• Novo Nordisk Chief Scientific Advisor, Dr Lotte Bjerre Knudsen
• MIT's Robert Langer
• Patient Keynote, Jimi Olaghere
• Northeastern University's Dr Mansoor Amiji
• Drug Delivery Technology Presentation Tracks
• Networking Opportunities
• and more

Want to know more about PODD? Check it out at PODDConference.com.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can best support their regulatory teams and engage with the FDA and other regulators. Specifically, the panelists address:

• Engaging with the FDA on a peer-to-peer level
• Effectively negotiating about innovative approaches that may be outside of guidelines
• How to react and respond to feedback and questions from the FDA

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

This podcast features a panel discussion from the 2024 PODD Conference with biopharma leaders about biomaterial approaches to develop implants that can deliver molecules and optimize for dose frequency. Specifically:

• Defining biocompatible materials and biomaterials
• Differences between small and larger molecules
• Benefits and challenges of implants

To learn more about the PODD conference, please visit Drug-Delivery.org.

Summary:
The consolidation of independent clinical trial sites into larger, integrated networks represents a strategic evolution in clinical research. This panel from the 2024 DPHARM conference discusses whether or not this level of consolidation can bring new researchers and new sites into clinical research, and lead to reduced risk to sponsors, increased predictability, streamlined site operations and greater access for patients. 

More specifically, this panel focuses on: 

• What is the true value of site networks?
• What does the landscape look like today – by TA/country / region?
• If scaled, what will the benefit look like for patients and can it impact the speed of treatment to patients?
• Case examples of the impact of current clinical research networks

In this panel:

• Mark Travers, PhD, MBA, VP, Head of GCTO Regions, Monitoring Excellence, Global Operations and eTMF, Merck
• Paul Evans, President and CEO, Velocity Clinical Research
• Mark Scullion, MBA, CEO, Atlas Clinical Research
• Nick Slack, MBE, Chairman and CEO, The START Center for Cancer Research

For more information, go to DPHARMconference.com. 

Summary:
Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO. 

More specifically:

• The current tailwinds working for and headwinds working against investment in biotech
• The increasing specialization of investors and lack of generalist investors 
• The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitors
• Where investors are more positive on biotech, and reasons for optimism in coming pipelines

For more information, visit IO360summit.com 

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part II of this podcast series covers the 16 Pharma from the Trenches track case studies.

In this podcast series, DPHARM Directors Valerie Bowling and Tracey Kimball break down what to expect at DPHARM 2025. Part I of this podcast series covers keynotes and key topics for this year's event, including:

• Former Merck CEO, Ken Frazier
• Former Head of FDA, Scott Gottlieb
• CRISPR Gene Therapy Patient Keynote, Victoria Gray
• Tuft's Ken Getz
• How DPHARM is tackling AI
• What to do about Protocol Complexity
• and more

Want to know more about DPHARM? Check it out at DPHARMconference.com.

About this podcast: 
Partnerships between industry and patient advocacy groups supply medicine development with critical patient expertise, insights and experience  on the journey towards greater patient centricity. This podcast focuses specifically on the role of patient advocacy groups in medicine development in providing a direct, and often untapped, resource for patient insights, community connections and protocol feedback. 

Dr Matthew Reaney, Scientific Lead, Patient-Centered Solutions at IQVIA, speaks with Trish Davidson, Senior Consultant at the Tufts Center for the Study of Drug Development and Director, PALADIN Consortium about the role of patient advocacy groups in medicine development and how PALADIN is connecting industry stakeholders to reduce duplicative efforts in patient engagement resources and advance more efficient patient engagement across the industry.

In the podcast, Matt touches upon IQVIA's recent collection of perspectives from researchers, approvers and patients. The book, Patient-centricity in the Biopharmaceutical Industry: Are We Nearly There Yet? was collated and edited by Matt and gathers diverse insights on patient-centric intervention development. In formats ranging from poetry to short fiction and personal narratives to more traditional reviews of the research, 30+ contributors across the industry discuss how to be truly “patient centric.” It can be accessed for free at https://bit.ly/PatientCentricityBook. 

For more information on PharmaTalk Radio podcasts, you can visit theconferenceforum.org.

This podcast features a panel discussion from the 2024 PODD Conference with pharma, medtech and academic leaders about technological development and patient and clinical adoption of closed-loop systems. Specifically:

• Success in diabetes and lessons for other indications like oncology and CNS
• New frontiers in improving closed-loop therapies
• Increasing access across therapy areas

To learn more about the PODD conference, please visit Drug-Delivery.org.

Patient-reported outcomes (PROs) are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how to incorporate PROs into clinical trials in ways that improve probabilities of success while avoiding common mistakes. Specifically, the panelists address:

• How PROs provide evidence on the effect of interventions on patient symptoms and quality of life, but by the nature of being subjective, they are prone to bias 
• The growth of electronic health technologies provides unprecedented opportunities to systematically collect PROs
• Disadvantages of electronic methods include technical difficulties, cost, longer start-up time, and “digital divide” between patients

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

Summary:
This podcast from the 2024 DPHARM conference showcases the value of patient engagement as a core strategic investment by focusing on the connection between patient engagement and tangible patient benefits / long-term business sustainability. 

The case example from Roche uses patient burden and protocol complexity in late-stage clinical development to demonstrate how this connection can be done in larger corporations and to emphasize patient engagement as a long-term growth driver and not just a short-term cost. 
More specifically: 

• Protocol design and executional practice, and the impact of current practices on protocol performance
• Framework, process and use cases for optimization of protocol performance through operationalization of patient preferences 
• Direct impact on corporate goals like recruitment, retention and growth 

For more information, go to DPHARMconference.com

Summary:
In this podcast from the 2024 CRAACO: Clinical Research as a Care Option conference, Dr Meredith Zozus, UT Health San Antonio, walks through several studies illustrating differences in data quality and scalability using EHRs in the conduct of structured protoocls versus retrospective studies using EHR. The results highlight the important methods and approaches for using EHR data in clinicla studies, which is a key component of integrating care and research. 

For more information, go to CRAACOevent.com.

Summary:
This podcast delves into the critical challenges of scalability in T-cell therapies (including CAR-T, TILs, and TCR-T). The panelists discuss the primary obstacles hindering the increased availability of T-cell therapies to patients, the most promising upcoming approaches to enhance access, the greatest opportunities to improve efficiencies and scalability, and the developments in the near future that could help meet growing demand. 

For more information, go to IO360summit.com. 

Summary:
This podcast focuses on the current state of patient centricity within the biopharmaceutical industry, how it's being implemented, operationalized and scaled within organizations, and showing the tangible value of engaging patients. 

Dr Matthew Reaney,  Scientific Lead, Patient-Centered Solutions at IQVIA, speaks with Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, to share their experiences, what they've seen in patient centricity gains, standing up patient centricity functions and proving the business case for doing so.

For more information, go to theconferenceforum.org.

Summary:
In this podcast, recorded at the 2025 Patients as Partners in Clinical Research conference, patient advocate and caregiver Dr Justin Hopkin, University of Rochester, describes his family's journey before, during and after his son was diagnosed with a rare, life-threatening disease. 

Dr Hopkin talks about the process of getting a diagnosis, the critical role of a clinical trial for his son, the impact on his other children, and his advice for medicine developers and clinical trial designers. 

For more information, go to PatientsAsPartnersConference.com

Summary:
This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.

More specifically: 

• Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
• Insights into how these developments could influence industry trends and investor sentiment
• Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies

In this podcast:

• Roy Baynes, MD, PhD, EVP & CMO at Eikon Therapeutics

• Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist Securities

For more information, go to IO360summit.com

This podcast features a panel discussion from the 2024 PODD Conference with pharma and biotech leaders about approaches and challenges in developing sustained release and long acting injectable formulations of therapeutics. Specifically:

• Contrasting approaches for both biologics and small molecules
• Next generation technologies to provide less frequent administration
• Scalable and sustainable ways to provide longer lasting treatments by going beyond conventional sustained release technologies

To learn more about the PODD conference, please visit Drug-Delivery.org.

Summary: 
In this session from DPHARM 2024, pharma experts in data science, digital innovation and development discuss the prerequisites for generative artificial intelligence (GenAI) to work well in large pharma organizations, the change management required to implement GenAI adoption, use cases and lessons learned, ensuring GenAI use is fit-for-purpose, and more. 

For more information, go to DPHARMconference.com.

Summary: 
New clinical trial execution models have been introduced over the last decade, providing local communities with more direct access to clinical research through remote sites, retail pharmacies, mobile units, site staff embedded in clinical care settings, and more. 

In this session, recorded at the 2024 CRAACO: Clinical Research as a Care Option conference, Joan Chambers of the Tufts Center for the Study of Drug Development shared preliminary survey results conducted by the Tufts CSDD to help industry understand the strategic and structural growth
of new trial sites and partnerships in bringing trials directly to local communities.

This podcast sheds light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinical trial landscape.

For more information, go to theconferenceforum.org.